Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Specific PHGKB|Pharmacogenomics PHGKB|PHGKB

Last Posted: Jun 08, 2023
spot light Spotlight

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
M Tsuboi et al, NEJM, June 4, 2023

In this planned final analysis of overall survival from the phase 3 ADAURA trial, adjuvant osimertinib resulted in significantly longer overall survival than placebo among patients with completely resected, EGFR-mutated, stage II to IIIA NSCLC as well as in the overall population (patients with stage IB to IIIA disease).

Translating predictive analytics for public health practice: A case study of overdose prevention in Rhode Island.
Bennett Allen et al. Am J Epidemiol 2023 5

Prior applications of machine learning to population health have relied on conventional model assessment criteria, limiting the utility of models as decision supports for public health practitioners. To facilitate practitioner use of machine learning as decision support for area-level intervention, this study developed and applied four practice-based predictive model evaluation criteria (implementation capacity, preventive potential, health equity, and jurisdictional practicalities). We used a case study of overdose prevention in Rhode Island to illustrate how these criteria could inform public health practice and health equity promotion.

Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
Antonio Passaro et al. JAMA Oncol 2023 5

The use of adjuvant chemotherapy for stage IB-IIIA resected non–small cell lung cancer (NSCLC) has limited benefit for improving cure rates. The proportion of epidermal growth factor receptor (EGFR) alterations among patients with resected NSCLC is comparable to that observed in patients with advanced disease, and the use of EGFR tyrosine kinase inhibitors (TKIs) has been demonstrated to prolong disease-free survival (DFS). With recent approval of osimertinib in this context, a focus on the rapidly evolving scenario and future perspective in clinical practice is needed and was the aim of the current review.

Cost-effectiveness of Pharmacogenomic Testing: How to Measure the Value of Having the Right Dose of the Right Drug for the Right Patient
L Shi et al, CDC Blog Post, May 8, 2023

A recent systematic review that assessed the cost-effectiveness of pharmacogenetic testing for drugs with existing guidelines concluded that most studies favored pharmacogenomic testing. The significance of this conclusion must be interpreted with caution and in the context of study factors, such as funding sources, geography, cohort, and the cost-effectiveness comparisons being made.

news Latest News and Publications
An updated examination of the perception of barriers for pharmacogenomics implementation and the usefulness of drug/gene pairs in Latin America and the Caribbean. External Web Site Icon
Aimeé Salas-Hernández et al. Front Pharmacol 2023 141175737
Evaluation of HLA-B*05, *07, *08, *27 and *51 Allele Expression in Adults with Immune Thrombocytopenic Purpura. External Web Site Icon
Niloofar Yazdani Rad et al. Maedica (Bucur) 2023 18(1) 61-66
Genome-wide analyses reveal novel opioid use disorder loci and genetic overlap with schizophrenia, bipolar disorder, and major depression. External Web Site Icon
Børge Holen et al. Addict Biol 2023 28(6) e13282
Mental Health Prescribers' Perceptions on the Use of Pharmacogenetic Testing in the Management of Depression in the Middle East and North Africa Region. External Web Site Icon
Shimaa Aboelbaha et al. Pharmgenomics Pers Med 2023 16503-518
Pharmacogenomics in practice: a review and implementation guide. External Web Site Icon
Danya Kabbani et al. Front Pharmacol 2023 141189976
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update. External Web Site Icon
Maria Gabriella Matera et al. Expert Opin Drug Metab Toxicol 2023
Inside the nascent industry of AI-designed drugs. External Web Site Icon
Carrie Arnold et al. Nat Med 2023 6
A model for the return and referral of all clinically significant secondary findings of genomic sequencing. External Web Site Icon
Rita Kodida et al. J Med Genet 2023
Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center. External Web Site Icon
Sarah A Morris et al. Am J Health Syst Pharm 2023
Prediction of Diagnosis and Treatment Response in Adolescents With Depression by Using a Smartphone App and Deep Learning Approaches: Usability Study. External Web Site Icon
Jae Sung Kim et al. JMIR Form Res 2023 7e45991


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.